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Abstract Tissue engineering aims at the creation of living
neo-tissues identical or close to their native human counter-
parts. As basis of this approach, temporary biodegradable
supporter matrices are fabricated in the shape of a desired
construct, which promote tissue strength and provide
functionality until sufficient neo-tissue is formed. Besides
fully synthetic polymer-based scaffolds, decellularized
biological tissue of xenogenic or homogenic origin can be
used. In a second step, these scaffolds are seeded with
autologous cells attaching to the scaffold microstructure. In
order to promote neo-tissue formation and maturation, the
seeded scaffolds are exposed to different forms of stimula-
tion. In cardiovascular tissue engineering, this “condition-
ing” can be achieved via culture media and biomimetic in
vitro exposure, e.g., using flow bioreactors. This aims at
adequate cellular differentiation, proliferation, and extracel-
lular matrix production to form a living tissue called the
construct. These living autologous constructs, such as heart
valves or vascular grafts, are created in vitro, comprising a
viable interstitium with repair and remodeling capabilities
already prior to implantation. In situ further in vivo
remodeling is intended to recapitulate physiological vascu-
lar architecture and function. The remodeling mechanisms
were shown to be dominated by monocytic infiltration and
chemotactic host-cell attraction leading into a multifaceted
inflammatory process and neo-tissue formation. Key mol-
ecules of these processes can be integrated into the scaffold
matrix to direct cell and tissue fate in vivo.
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Introduction
The ultimate goal of any tissue engineering approach is the
creation of autologous living neo-tissues similar in archi-
tecture and function to native human structures. Therefore,
an accurate understanding of the fundamentals of native
tissue—representing the “gold standard”—constitutes a
prerequisite to a successful development of native analo-
gous tissue-engineered substitutes. Interestingly, it is the
research on tissue engineering of recent years, which has
fundamentally stipulated a novel interest in embryology,
native tissue architecture, and development. In cardiovas-
cular medicine, the in vitro fabrication of heart valves
represents an example of how tissue engineering solutions
aim to overcome obvious clinical limitations of currently
available treatment options (Fig. 1). Native heart valves are
composed of living, dynamic tissue capable of continuous
remodeling to adapt to the constantly alternating hemody-
namic environment [1]. None of the currently available
valvular replacements are capable of fully restoring the
native function due to insufficient adaptive capacity. State-
of-the-art prostheses in today's clinical use show consider-
able limitations. These include the lack of growth, repair
and remodeling capabilities, once they are implanted into
the body. Additionally, mechanical valve substitutes are
inherently susceptible to thromboembolic events due to
high shear stress, nonphysiological flow profiles, and blood
damage necessitating lifelong anticoagulation therapy [2,
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3]. Bioprostheses from xenogenic or homogenic origin are
inherently prone to structural degeneration, and the associ-
ated need for repeat reoperations makes them less suitable
for many patients [4, 5]. Tissue engineering of heart valves
represents a technology with the potential to overcome
these limitations by creating a living autologous valve
replacement that prevents an immune response, clotting
activation, and valvular degeneration on the one hand, and
allows for growth, remodeling, and repair throughout the
patient's lifetime on the other hand.
The basis of most tissue engineering approaches is the
fabrication of temporary supporter matrices in the shape of
a desired construct. These biodegradable matrices promote
tissue strength and provide functionality during the engi-
neering process until sufficient neo-tissue is formed to
restore adequate physiological function. In cardiovascular
tissue engineering, fully synthetic polymer-based scaffolds,
as well as decellularized biological tissue of xenogenic or
homogenic origin, can be used. After in vitro tissue
formation, the living autologous constructs are implanted
into the patient, where further in vivo remodeling is
intended to recapitulate physiological vascular architecture
and function. This step of in situ remodeling represents an
essential part of the tissue engineering concept, as it will
fundamentally influence the fate and success of the
substitute. The mechanisms involved in this remodeling
process were shown to be mainly dominated by monocytic
infiltration and host-cell attraction to the construct; however,
little is known about the actual molecular and cellular
pathways involved, which are central for this essential
reorganization of bioengineered implants.
Strategies in tissue engineering: in vivo or ex vivo?
Tissue engineering is defined as an interdisciplinary field,
applying the principles and methods of engineering to the
development of biological substitutes that can restore,
maintain, or improve tissue formation [6]. According to
this predefinition, two principle strategies have been
developed to generate living autologous replacements:
The in vitro as well as the in vivo approach. The first
approach, requires an ex vivo phase generating the optimal
native-like substitute in vitro. This traditional tissue
engineering paradigm comprises the isolation and expan-
sion of cells from the patient, subsequent seeding onto an
appropriate scaffold material, in vitro tissue formation and
finally, implantation into the patient from whom the cells
were taken (autologous approach). This paradigm, further
referred to as the in vitro tissue engineering approach, being
employed as the principal approach for heart valve tissue
engineering and is aimed at full development of the tissue
substitute ex vivo (see Fig. 1). Several different cell sources
serve as the basis for the generation of these constructs,
where minimally invasively accessible stem and progenitor
cells have shown tremendous potential [7–9].
The second approach of in situ heart valve tissue
engineering circumvents the in vitro tissue culture phase
by straight implantation of natural tissue-derived heart
valve matrices, aiming at potential cell in-growth and
remodeling in vivo [10]. In recent years, a further approach
has emerged—mainly driven by the advances in stem cell
technology and signaling. By seeding the construct with
autologous cells, such as progenitor and/or mononuclear
cells, using a cell carrier matrix, host-cells can be attracted
to the implant site via chemo-attractive paracrine pathways.
These attracted immune cells then support a distinct
remodeling process, resulting in enhanced extracellular
matrix and collagen formation [11].
The in vitro fabrication of an autologous construct:
steps in cardiovascular tissue engineering
According to the approach of in vitro tissue engineering
techniques, such as heart valve tissue engineering, the
successful fabrication of autologous living replacements
similar to the native benchmark is supported by three main
elements: (1) autologous cells that resemble their native
counterparts in phenotype and functionality are isolated and
expanded using standard cell culture methods. For this
purpose, several different sources are available, ranging
from mature vascular-derived cells to prenatally harvested
fetal progenitor cells. (2) The cells are seeded onto a
temporary biodegradable supporter matrix fabricated in the
shape of a trileaflet heart valve, termed the scaffold, which
promotes tissue strength until the produced ECM (extracel-
lular matrix) provides functionality on its own. Several
different matrix materials, including synthetic as well as
biologic materials, have been assessed for these purposes
Fig. 1 Tissue-engineered heart valve. Autologous living tissue-
engineered heart valve before implantation after in vitro conditioning
in a bioreactor system
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[12]. (3) In order to promote tissue formation and
maturation, the seeded scaffolds are exposed to mechanical
stimulation transmitted via a culture medium (biological
stimuli) or via “conditioning” of the tissue in a bioreactor.
This bioreactor phase targets at the in vitro generation of a
matured, high-quality extracellular matrix, having the
capacity to grow as well as being able to respond to
varying physiological needs and to repair structural injury
by remodeling [13, 14; Fig. 2].
Cell sources for cardiovascular tissue engineering:
from vascular cells to stem cells
The in vitro formation of a durable, well-structured and
viable tissue is crucial for the in vivo functionality of a
tissue-engineered construct. In this context, the choice of
the optimal cell source is critical for the quality and long-
term success of heart valve tissue engineering [1, 15;
Fig. 2]. An established approach for heart valve tissue
engineering uses cells originating from aortic, saphenous
vein, or peripheral artery biopsies [15]. Out of these
vessels, two cell types can be isolated: Endothelial cells
(ECs) with antithrombogenic properties and myofibroblasts
capable of ECM development [16–18]. After preliminary
studies, mainly in sheep [16–21], the potential of human
vascular-derived cells was evaluated by seeding on biode-
gradable scaffolds and revealed excellent tissue formation
[15, 22, 23]. A promising alternative cell source for
regenerative medicine is bone marrow-derived stem cells
(BMSCs) [3, 24, 25]. BMSCs were successfully used for in
vitro production of heart valves [24, 26], and have been
implanted in vivo demonstrating adequate functionality
[27].
To improve the functional capacities and to reduce the
risk for complications [28] tissue-engineered heart valves
are usually covered with autologous human ECs [18].
Differentiated ECs have been isolated from vascular
sources exhibiting promising results in heart valve tissue
engineering [16, 19, 20, 22]. Furthermore, endothelial
Fig. 2 Concept of cardiovascular
tissue engineering. Autologous
cells are harvested from the patient
and expanded in vitro. When
sufficient numbers are reached,
cells are seeded onto a biodegrad-
able scaffold. Constructs are either
positioned in a bioreactor and
conditioned (in vitro approach) or
directly implanted into the patient
(in vivo approach). After implan-
tation of the tissue-engineered
construct, the proposed mecha-
nism of vascular remodeling
comprises an early monocyte
recruitment to the scaffold with the
release of multiple angiogenic
cytokines and growth factors.
These factors (i.e., VEGF) cause
recruitment of host cells, such as
MC, SMCs, and ECs, to the
scaffold. The invading host cells
originate from circulating
progenitors and (trans-anastomotic)
migration/in-growth of mature
vascular cells from adjacent vessel
segments. Incoming ECs and
SMCs appropriately organize into a
mature blood vessel structure on
the luminal surface of the scaffold
(with the remaining scaffold in the
center of the construct). As the
scaffold degrades, early monocytes
migrate away, leaving behind a
remodeled, completely autologous
neo-vessel
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progenitor cells (EPCs), discovered in human blood [29],
have been established as source of ECs [30, 31]. Since
they are easily accessible, current research aims at their
trans-differentiation into myofibroblast-like cells to estab-
lish blood as single cell source for heart valve tissue
engineering.
Another interesting cell source is the umbilical cord,
containing several cell types that can be used for heart
valve tissue engineering: (1) umbilical cord vein-derived
and artery-derived cells, (2) Wharton's Jelly-derived MSCs,
and (3) umbilical cord blood-derived EPCs. These cells
demonstrated excellent growth properties and tissue forma-
tion [32–35]. Vascular neo-tissues were produced using
human umbilical cord blood-derived EPCs seeded on
vascular scaffolds [36]. By using umbilical cord-derived
cells several different cardiovascular replacements could be
generated [37–40].
The ideal pediatric tissue engineering paradigm com-
prises a prenatal fetal cell harvest allowing for tissue
engineering processes during pregnancy followed by the
implantation of the autologous tissue-engineered construct
directly after birth. A new concept, using human prenatal
progenitor cells derived from chorionic villi and umbilical
cord blood for the production of autologous heart valve
leaflets, has been introduced by Schmidt et al. [9].
Furthermore, human amniotic fluid-derived cells, as an
easily accessible cell source, have been used as a sole cell
source for the fabrication of living autologous heart valves
prior to birth [8, 41].
Human adipose tissue contains mesenchymal stem cells
with the potential to differentiate into various phenotypes in
vitro [42, 43] and in vivo [44]. Due to the high availability
and the ease of harvest, adipose-derived stem cells
(ADSCs) represent a potential alternative stem cell source
to BMSCs [45].
Biocompatible starter matrices: the optimal scaffold
for cardiovascular tissue engineering
The development of scaffolds for heart valve tissue
engineering has proceeded along two fronts: a biological
matrix material and a fully synthetic scaffold [46].
Regardless of the material of the scaffold matrix, the design
of a scaffold capable of supporting cellular growth and of
withstanding mechanically complex cardiovascular envi-
ronment is critical to the success of the tissue-engineered
construct. In addition to meeting all the standard design
criteria of traditional tissue valves, in which durability and
biocompatibility are effectively passive attributes of the
underlying materials, and selecting the best scaffold
material, it requires consideration of the active behavior of
the cells in the regulation of tissue growth, remodeling, and
homeostasis. These matrices must be able to support cell
growth and cell-to-cell interaction guiding tissue formation
into a functional organ with organotypic ECM. The surfaces
of these starter vehicles must be biocompatible, allowing
cellular ingrowth and the formation of antithrombogenic cell
linings, and biodegradable, providing an optimized degrada-
tion rate for cellular expansion [13]. These specific require-
ments entailed the development of various approaches to
identify the optimal scaffold material, including the creation
of synthetic [12] and biological scaffold materials [47].
These can be further subdivided into native tissue-derived
ECM scaffolds [48], polymeric scaffolds [49–53],
biological-polymeric hybrid scaffolds [54–56], and collagen
or fibrin gel scaffolds [57–60]. Although significant advan-
ces have been made in all these approaches, the polymeric
scaffolds have, to date, received most attention regarding
heart valve tissue engineering applications.
Polymeric starter matrices for cardiovascular tissue
engineering: the future of autologous tissue replacement
The use of polymeric scaffold materials for different tissue
engineering approaches has already been broadly demon-
strated [12]. The ideal scaffold matrix for heart valve tissue
engineering has to be at least 90% porous [61], and
comprises an interconnected pore network, as this is
essential for cell growth, nutrient supply, and removal of
metabolic waste products. Besides being biodegradable,
biocompatible, and reproducible, the scaffold material
should also display a cell-favorable surface chemistry and
match the bio-mechanical properties of the native heart
valve tissue [12]. In addition, the rate of matrix degradation
should be controllable and commensurate with the rate of
novel tissue formation in order to provide a sufficient but
reducing mechanical stability of the construct over time [1,
62]. Several synthetic biodegradable polymers have been
investigated as potential starter matrices for heart valve
tissue engineering that vary in their manufacturing possi-
bilities and degradation rates (Table 1).
Aliphatic polyesters, including polyglactin (PG), poly-
glycolic acid (PGA), and polylactic acid (PLA), degrade by
cleavage of the polymer chains due to hydrolysis of their
ester bonds. The resulting monomer is either excreted via
urinal secretion or enters the tricarboxylic acid cycle [61].
In order to fabricate single heart valve leaflets, the creation
of scaffolds was initially based on combinations of aliphatic
polyesters, including PG non-woven PGA meshes with
layers of PGLA and non-woven PGA meshes. The major
limitations of aliphatic polyesters, when used as a sole
material, are their thickness, initial stiffness, and non-
pliability, making the fabrication of trileaflet heart valves a
difficult process.
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A further group of widely used polymers is the polyhydrox-
yalcanoates (PHA) family, which is composed of polyesters
built up from hydroxyacids that are produced as intracellular
granules by various bacteria [63]. PHAs, as well as poly-4-
hydroxybutyrate, have been used to create trileaflet heart valve
conduits [22, 64]. These materials possess thermoplastic
properties and can be molded into any desired shape using
stereolithography [22, 65]. A limitation of PHAs can be found
in their slow degradation. Combinations of aliphatic polyesters
and PHAs have also been tested as alternative composite
materials [19, 66]. Particularly, the use of PGA coated with
P4HB (Fig. 3), combining the thermoplastic properties of
P4HB and the high porosity of PGA, for the fabrication of
complete trileaflet heart valves revealed promising results in a
rapidly growing sheep model [8, 19, 26, 66, 67].
Decellularized tissue-derived matrices: the biologic
counterpart
In principal, donor heart valves (homografts) or animal-
derived heart valves (xenografts) are among the most
obvious choices for scaffold materials. They are fixed
and depleted of cellular antigens, which makes them less
immunogenic, and/or thus eligible to be used as a
scaffold material in tissue engineering. The removal of
cellular components results in a template composed of
extracellular matrix proteins that serve as an intrinsic
medium for subsequent cell attachment. Nevertheless,
they still possess a native-like geometry and architecture
with bio-mechanical and hemodynamic properties similar
to their native counterpart [8, 13, 67].
Various decellularization techniques have been exten-
sively investigated in order to minimize the residual
immunologic potential of biological matrices. Although it
is essential to remove all cellular components, the decellu-
larization treatment should avoid any harm or alteration of
the ECM properties. This preservation of matrix integrity,
as well as the efficiency of cell removal is highly dependent
on the method used for decellularization [68]. Several
different decellularization methodologies for heart valve
scaffold fabrication have been reported, including trypsin/
EDTA [68–71], freeze drying [72], osmotic gradients [73],
non-enzymatic detergent treatment [68, 74], and multistep
enzymatic procedures [75]. The use of non-enzymatic
detergent-based techniques has been shown to result in a
much more efficient cell removal, while preserving the
overall matrix integrity of the scaffold, when compared to
other more aggressive decellularization methods such as
trypsin/EDTA [68, 76, 77]. In order to avoid this
impairment of the matrix integrity and function due to
tissue-derived protease activation, the use of suitable
protease inhibitors has been recommended [78]. Accesso-
rily, nuclease digestion steps should be embedded into the
decellularization procedure to remove any residual RNA or
DNA within the scaffold.
Several in vivo studies have proven the feasibility to use
decellularized scaffolds as starter matrix for cardiovascular
tissue engineering [79, 80]. Moreover, first clinical trials
have been initiated [81]. However, using xenogenic
materials, serious complications have been reported due
Table 1 Examples of polymeric starter matrices used for cardiovascular tissue engineering
Scaffold Construct Reference
Lactide acid and P-caprolactone and PGA/PLLA Vascular autograft 16, 17, 20, 99
PEUU and PEEUU Vascular patches 100
PGA Vascular patches/graft 18, 21, 66
P4HB Vascular graft 66
PHA Vascular graft 66
PHO TEHV 22
PGA/P4HB THEV 8, 9, 19, 27, 68, 69
PGA polyglycolic acid; PHA polyhydroxyalkanoate; PHO polyhydroxyoctanoate; PEUU poly(ester–urethane)urea; PEEUU poly(ether–ester–
urethane)urea; PLLA polylactic acid; P4HB poly-4-hydroxybutyrate; TEHV tissue-engineered heart valve
Fig. 3 The matrix for cardiovascular tissue engineering. SEM images of
the PGA mesh coated with P4HB at low (a) and high (b) magnification
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to residual α-Gal-mediated immunogenicity [81, 82].
Furthermore, the use of xenografts principally involves
the risk of zoonoses and prionic diseases, in terms of
human diseases caused by animal-derived infectious
agents, which has given rise to widespread concern [83,
84]. When the matrix material is from homogenic origin,
the limited availability of donor valves and associated
ethical concerns represent a considerable shortcoming.
Moreover, the lack of evidence of growth and remodeling
capacities of valve replacements when using decellular-
ized scaffolds seems to be a further drawback, especially
with regard to the pediatric field [9]. These drawbacks and
uncertainties raise a common concern associated with the
use of decellularized starter matrices, also fuelling the
search for synthetic scaffold alternatives.
Implant-mediated inflammation: the key to optimal
tissue remodeling?
Healing of a tissue-engineered constructs in vivo has to
be seen as a continuous but multifaceted process.
Following the initial blood-material interactions, inflam-
matory processes occur around the implanted construct.
The extent of this response depends upon the degree of
maturation of the tissue-engineered construct and the
extent of surgical injury, which directs a physiological
healing reaction, consisting first of an acute inflamma-
tion, followed by repair processes. Immediately after
implantation, phagocytic cells (predominantly neutrophils
and monocytes) migrate from the microcirculation to the
interface between the implant surface and the injured
tissue. The inflammatory phase, (which lasts up to
several weeks in humans) consists of phagocytic removal
of debris due to trauma, and then, provides the
appropriate signals for the shift from inflammation to
repair and remodeling of the tissue. Taken as a whole,
two main processes seem to be indispensable for a
successful remodeling of tissue-engineered constructs in
vivo: (1) The formation of an atypical vascular response
to injury at the luminal surface, including intimal
thickening, pannus formation, and neointima develop-
ment, and (2) deep tissue biomaterial-associated effects
of foreign body reaction, granulation, tissue formation,
and fibrosis forming a media-like structure [85].
Upon resolution of the acute inflammatory reaction,
monocytes are observed within the implanted construct.
Indeed, it has been demonstrated that monocyte chemotac-
tic protein (MCP-1), a potent monocyte-attracting cytokine,
is expressed by activated neutrophils at the implant site, and
thus, seems to play a central role within the early
remodeling phase, which is mainly characterized by
chemotactic immune cell infiltration [86]. While the exact
roles recruited monocytes play in the implant transforma-
tion remains largely conjectural, their role in tissue repair is
better understood. Recent findings suggest that monocytes
remain within the implant scaffold until it fully degrades,
and therefore, may play a role in the entire remodeling
process. At 100-week follow-up, diffusemononuclear inflam-
mation, particularly in areas of residual polymer fibers, has
been observed [87]. In implanted tissue-engineered vascular
grafts, recent evidence suggests that monocytes produce
important cytokines (i.e., MCP-1/CCL-2, IL-6, IP-10),
growth factors, and proteases necessary for vascular cell
proliferation/migration and appropriate vascular remodeling
[85, 88, 89].
Monocytes/macrophages at the site of long-term implan-
tation express ECM remodeling proteases (i.e., MMPs),
cytokines characteristic of the innate immune response (IL-
1α, IL-1β, IL-6, IL-10, and TNFα) and cell adhesion
(ICAM-1, VCAM-1). Moreover, monocytes involved in a
pro-fibrotic foreign body response have been shown mainly
properties of classically activated macrophages (IL-1β, IL-
6, TNF, Ccl20, Cxcl10), and to a lesser extent, wound-
healing (factor XIII-A) and regulatory macrophages (IL-10;
[90, 91]). While these monocyte properties may affect
implant integration (foreign body response vs. tissue
integration) via paracrine signaling, the precise role of
monocytes/macrophages in tissue remodeling is not under-
stood. However, expression of angiogenic cytokines
(VEGF) from implant-associated monocytes/macrophages
has lead to a more descriptive understanding of their role in
implant neovascularization.
In vivo animal studies have revealed that arteriogenesis
depends on circulating monocytes and macrophage accu-
mulation. This finding has been confirmed by recent
studies, which demonstrate that monocyte recruitment is
central to postnatal blood vessel formation [92–94]. This
mechanism has, in part, been attributed to the critical role of
VEGF in adult neovascularization, and prevention of neo-
vessel regression [95–97]. Indeed, monocyte/macrophage
infiltration associates with VEGF expression with the
tissue-engineered constructs [98]. In addition to VEGF,
recruited monocytes likely release multiple cytokines, which
then orchestrate the proper vascular neovascularization of
biodegradable implants.
Besides the involvement of MCP-1 for monocytic
attraction and VEGF expression, the molecular pathways
of these remodeling phenomena remain largely unknown.
The discovery of these underlying pathways seems
indispensable for the development of strategies to modulate
early inflammatory reactions and enhance remodeling [99].
First success has been achieved by attaching MCP-1-
releasing biodegradable microparticles to the scaffold
matrix in order to mimic the chemo-attractive properties
of seeded cells in vivo [98].
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Conclusions
Cardiovascular tissue engineering is a promising approach
aiming at the creation of living functional autologous
replacements and holds exciting potential for improving
therapy of many diseases. However, before clinical appli-
cation of the tissue engineering concept becomes routine,
numerous steps must be overcome in the laboratory.
Primary amongst these is the limited knowledge about the
mechanisms involved in the in vivo remodeling process of
tissue-engineered constructs after implantation. Although
having first indications as to the influence of cytokine-
mediated monocyte-attraction and neovascularization, the
underlying exact molecular pathways remain unknown.
Another important consideration concerns the definition of
the ideal matrix material for engineering, providing a
template for directing new tissue growth and organization,
as well as for regulating cellular adhesion, migration, and
differentiation. The mechanism involved in neo-vascular
formation displays many parallels to natural neovasculari-
zation and may provide further insights into the biology of
these processes. However, although similarities to natural
processes exist, the development of a tissue-engineered
construct does appear to be a distinct process of vascular
formation in itself. A better understanding of how the
different steps of in vivo remodeling start and are controlled
will lead to a new class of implants. Moreover, the
identification and attachment of important regulatory
molecules to the scaffold matrices, such as VEGF, may
provide engineers with the key to enhance the body's innate
ability to regenerate implanted constructs. Eventually, this
could allow for the fabrication of “intelligent” scaffold
materials incorporating specific signaling molecules that
direct tissue fate within the implanted constructs.
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